Atogepant Improved Patient-Reported Outcome (PRO) Measures of Activity Impairment in Migraine-Diary and Headache Impact Test in a 12-Week, Double-blind, Randomized Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine (1454)
Neurology | December 7, 2023 | Volume: 96 | Issue: 15_supplement | Pages: No page available
10.1212/wnl.96.15_supplement.1454